Stelara (Ustekinumab) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Stelara (Ustekinumab) is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), key proteins involved in inflammatory and autoimmune processes. It is commonly used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

The main indications for Stelara (Ustekinumab) include plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and other related conditions. Plaque psoriasis is a chronic autoimmune disorder marked by rapid skin cell buildup, resulting in scaly, inflamed patches, often affecting the scalp, elbows, and knees. Stelara can be administered via subcutaneous injection or intravenous infusion and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is indicated for pediatric, adult, and geriatric patients.

Tariffs have influenced the stelara market by increasing costs for monoclonal antibody production inputs, sterile packaging, and temperature-controlled transportation. These cost pressures have affected hospital pharmacy and specialty clinic procurement, especially in regions relying on imported biologics. Asia-pacific and middle east markets face higher pricing sensitivity due to cross-border sourcing. On the positive side, tariffs have encouraged regional biologics manufacturing, strengthened local supply chains, and supported long-term treatment access for autoimmune patients.

The stelara (ustekinumab) market research report is one of a series of new reports from The Business Research Company that provides stelara (ustekinumab) market statistics, including stelara (ustekinumab) industry global market size, regional shares, competitors with a stelara (ustekinumab) market share, detailed stelara (ustekinumab) market segments, market trends and opportunities, and any further data you may need to thrive in the stelara (ustekinumab) industry. This stelara (ustekinumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stelara (ustekinumab) market size has grown strongly in recent years. It will grow from $11.85 million in 2025 to $12.54 million in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to limitations of conventional immunosuppressants, rising prevalence of autoimmune diseases, strong clinical efficacy data, hospital-based biologic administration, demand for durable remission.

The stelara (ustekinumab) market size is expected to see strong growth in the next few years. It will grow to $15.57 million in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growth in inflammatory bowel disease cases, expansion of biologic reimbursement coverage, patient preference for less frequent dosing, biosimilar competition impact, improved biologic delivery devices. Major trends in the forecast period include rising use of targeted biologic therapies, expansion of autoimmune disease indications, shift toward long-term maintenance treatment, growing adoption of subcutaneous biologics, increase in home-based administration.

The increasing prevalence of psoriasis patients is expected to drive the growth of the Stelara (ustekinumab) market in the coming years. Psoriasis is a chronic autoimmune disorder that accelerates skin cell turnover, resulting in red, scaly patches. The rising prevalence of psoriasis is influenced by factors such as improved diagnosis, environmental triggers, genetic predisposition, and an aging population. Stelara (ustekinumab) works by targeting and inhibiting interleukin-12 and interleukin-23, helping psoriasis patients by reducing inflammation and plaque formation, improving skin clearance, and supporting long-term symptom management, ultimately enhancing quality of life. For example, in August 2024, the National Psoriasis Foundation (NPF), a US-based non-profit organization, reported that psoriasis affects approximately 3% of U.S. adults aged 20 and above, representing over 7 million individuals. Additionally, around 600,000 adults in the U.S. are believed to have psoriasis but remain undiagnosed. Consequently, the rising prevalence of psoriasis patients is expected to propel the growth of the Stelara (ustekinumab) market.

Key companies in the Stelara (ustekinumab) market are developing innovative products, including biosimilars, to offer cost-effective treatment options for patients with chronic inflammatory conditions. Stelara biosimilars are biologically similar medications designed to replicate the therapeutic effects of Stelara (ustekinumab), targeting IL-12 and IL-23 to treat autoimmune conditions such as psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's STELARA (ustekinumab). IMULDOSA offers broad indications, treating adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and ulcerative colitis. It is also approved for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, making it a versatile option across age groups. This extensive coverage positions IMULDOSA as a valuable choice for managing various immune-mediated inflammatory diseases.

In December 2023, Lotus Pharmaceutical, a Taiwan-based company, partnered with Favorex Pte Ltd., a Singapore-based pharmaceutical firm, to introduce a biosimilar of ustekinumab to the South Korean market. Through this partnership, Lotus Pharmaceutical aims to leverage Favorex's expertise and market presence to meet the demand for cost-effective biologic therapies and expand its footprint in the region's pharmaceutical sector.

Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson

North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the stelara (ustekinumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The stelara (ustekinumab) market consists of sales of small-molecule drugs, vaccines, immunotherapy products, biosimilars and injectable drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Stelara (Ustekinumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses stelara (ustekinumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for stelara (ustekinumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stelara (ustekinumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Other Indications
• 2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 4) By End User: Pediatric; Adult; Geriatric
• Companies Mentioned: Johnson & Johnson
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.